Company (Country; Symbol)

Company* (Country; Symbol)

Type/Product Area

Terms/Details (Date)


Acrux Ltd.* (Australia)

Vivus Inc. (VVUS)

Exclusive U.S. licensing deal under which Vivus got rights to Testosterone MDTS and Estradiol MDTS for treating low sexual desire and menopausal symptoms, respectively

Vivus will pay $3M in license fees over 17 months, up to $10.3M in milestones, and royalties on any sales; MDTS is a metered-dose transdermal delivery system (2/12)

Affymetrix Inc. (AFFX)

Silicon Genetics Inc.*

Agreement to integrate their technologies to improve productivity and throughput in functional genomics research

The deal is the second between the companies; terms were not disclosed (2/11)

AlgoNomics NV* (Belgium)

Pevion Biotech Ltd.* (Switzerland)

Collaboration on the rational design of RSV-derived peptides based on AlgoNomics' Tripole technology

The companies plan to design a vaccine for respiratory syncytial virus; terms of the 1.5-year deal were not disclosed (2/25)

Antares Pharma Inc. (OTC BB:ANTR)

ProSkelia SAS* (France)

Deal for development and potential licensing of products using Antares' ATD gel technology

The technology would be used to deliver undisclosed ProSkelia compounds; terms were not disclosed (1/8)

Archemix Corp.*

Nuvelo Inc. (NUVO)

Collaboration to develop Archemix's thrombin inhibitor, ARC183, for use in acute anticoagulant applications

Archemix gets an up-front payment and development and milestone payments; the companies will split costs and ownership of resulting products (1/12)

Array BioPharma Inc. (ARRY)

Genentech Inc. (NYSE:DNA)

Collaboration to advance two of Array's oncology programs into clinical development

Array will get up-front and research funding, as well as potential milestones and royalties; Genentech has development and commercialization responsibility and has the right to add additional programs to the collaboration (1/5)

Bioenvision Inc. (AMEX:BIV)

ILEX Oncology Inc. (ILXO)

ILEX converted its option on clofarabine for cancer applications in the U.S. and Canada into an exclusive sublicense

Bioenvision received $3.5M from ILEX unit ILEX Products Inc. and retains all other rights to the product; specific terms were not disclosed (2/2)

Biosite Inc. (BSTE)

Amylin Pharmaceuticals Inc. (AMLN)

Deal under which Biosite will develop Omniclonal antibodies for targets provided by Amylin

Biosite will get development fees and get certain exclusive diagnostic rights to the targets; Biosite would pay royalties on any resulting diagnostic sales (2/2)

Cellectis SA* (France)

Regeneron Pharmaceuticals Inc. (REGN)

Regeneron got rights to use homologous recombination technology for replacing or inserting a gene in the mouse genome

Regeneron will use the technology in its Velocigene platform; terms of the deal were not disclosed (2/11)

Cellectis SA* (France)

Diversa Corp. (DVSA)

Diversa licensed nonexclusive research rights to I-Scel, a natural endonuclease used to induce a double-strand break in the genome of a host organism

Diversa has an option to get a commercial license; terms of the deal were not disclosed (1/6)

Celltech Group plc (UK; LSE:CLL)

Biogen Idec Inc. (BIIB)

Collaboration on R&D of antibodies against the CD40 ligand protein for treating autoimmune diseases

Celltech will do all work through Phase I, at which point Biogen could invest in further development and the companies would share costs and profits; Biogen could get royalties if it doesn't exercise the option (2/5)

Chromos Molecular Systems Inc. (Canada; TSE:CHR)

AviGenics Inc.*

AviGenics acquired exclusive rights to Chromos' ACE System to generate transgenic avians for developing protein therapeutics and related uses

Chromos will receive up-front and annual license fees and could get milestone payments and royalties on ACE-derived products, as well as revenues on services AviGenics provides to third parties (2/3)

Collegium Pharmaceuticals Inc.*

Cypress Bioscience Inc. (CYPB)

Cypress exercised its option to license technology surrounding milnacipran developed by Collegium under their August 2002 deal

The goal is to develop improved versions of Cypress's milnacipran; Collegium gets a license payment and could earn milestone and royalty payments (1/26)

Crucell NV (the Netherlands; CRXL)

Biogen Idec Inc. (BIIB)

Biogen got a nonexclusive license to use Crucell's PER.C6 cell line for producing recombinant proteins to be used in antibody discovery programs

Crucell will receive up-front and annual payments, as well as royalties on sales of products discovered using the technology (1/15)

Dendreon Corp. (DNDN)

Nuvelo Inc. (NUVO)

Nuvelo licensed Dendreon's recombinant nematode anti- coagulant protein c2

Dendreon is getting $4M in cash and stock up front, as well as potential milestones and royalties; Nuvelo gets worldwide rights (2/4)

Discovery Partners International Inc. (DPII)

Celltech Group plc (UK; LSE:CCH)

Collaboration on discovery of lead compounds for a Celltech intracellular signal transduction target

DPI will use its compound collection and discovery tools in the deal, terms of which were not disclosed (2/4)

EntreMed Inc. (ENMD)

Alchemgen Therapeutics Inc.*

Alchemgen got rights in Asia to the endostatin and angiostatin proteins

At the same time, EntreMed assigned rights in the rest of the world to Children's Medical Center Corp.; EntreMed gets upfront and potential cash and royalty payments (2/4)

Evotec OAI AG (Germany; FSE:EVT)

Rib-X Pharmaceuticals Inc.*

Evotec will use its medicinal chemistry and parallel synthesis platform to facilitate Rib-X's efforts to identify antibiotics for clinical development

Terms of the deal were not disclosed (1/14)

Generex Biotechnology Corp. (Canada; GNBT)

Unihart Biotech Pharma* (the Netherlands)

Agreement to study the use of the RapidMist delivery system with Unihart's Oroferone, a liquid natural interferon

Generex will make formulated Oroferone to be delivered with its RapidMist device; terms of the deal were not disclosed (1/20)

Genomics Collaborative Inc.*

Sention Inc.*

Deal under which GCI will oversee a blood sample/DNA collection and banking effort in support of Sention research

Terms of the deal and the Sention area of focus were not disclosed (2/16)

Infectio Diagnostics Inc.* (Canada)

Chiron Corp. (CHIR)

Chiron licensed IDI's nucleic acid-based technology for detecting bacterial contamination in platelets and blood products

IDI also will transfer the technology, including R&D and manufacturing, to Chiron over the next two years; terms of the deal were not disclosed (1/5)

Inex Pharmaceuticals Corp. (Canada; TSE:IEX)

Enzon Pharmaceuticals Inc. (ENZN)

Collaboration under which Enzon gets exclusive North American rights to Inex's Onco TCS cancer drug for all indications

The deal could be worth $75M to Inex and includes $12M up front, $20M upon FDA approval and milestone and sales bonus payments of $43.75M; Inex also would get a percentage of sales and could co-promote the product (1/20)

Ingenium Pharmaceuticals AG* (Germany)

Gruenthal GmbH* (Germany)

Ingenium will develop animal models with defined gene alterations for use by Gruenthal in its program in pain

Ingenium will use its Ingenotyping technology in the deal, the terms of which were not disclosed (2/25)

Infinity Pharmaceuticals Inc.*

Amgen Inc. (AMGN)

Amgen got nonexclusive access to a collection of small molecules for three years and can screen broadly against multiple targets

Amgen made a $25M equity invesment for a stake of less than 15% in Infinity; Amgen will make additional payments over the three years, and could make milestone and royalty payments (1/8)

Inproteo*

Genentech Inc. (NYSE:DNA)

Genentech got a license to a patent on a fusion-protein purification technique known as "His Tag," and its foreign counterparts

The license covers all uses of the technology; terms were not disclosed (1/21)

Inproteo*

ZymoGenetics Inc. (ZGEN)

ZymoGenetics got a license to a patent on a fusion-protein purification technique known a "His Tag," and its foreign counterparts

The license covers all uses of the technology; terms were not disclosed (1/9)

Medarex Inc. (MEDX)

Xerion Pharmaceuticals AG* (Germany)

Collaboration to develop fully human antibodies using targets from Xerion and antibody tech- nology from Medarex

The companies will equally share the costs and responsibilities of resulting product development; target areas were not disclosed (1/20)

Myriad Genetics Inc. (MYGN)

Chemicon International Inc. (unit of Serologicals Corp.; SERO)

Exclusive licensing agreement granting Chemicon research use of several Myriad tumor- suppressor and breast cancer susceptibility proteins and antibodies

The agreement excludes commercial therapeutic and diagnostic rights; terms were not disclosed (1/14)

Noven Pharmaceuticals Inc. (NOVN)

Endo Pharmaceuticals Inc. (ENDP)

Endo licensed U.S. and Canadian rights to Noven's transdermal fentanyl patch, for which an abbreviated NDA is on file with the FDA for pain applications

Noven received $8M up front and would get $5M to $10M upon the first sale; Noven will manufacture the product and they will share profits on undisclosed terms; also, the companies established a collaboration to develop additional transdermal products (2/26)

PPL Therapeutics plc (UK; OTC BB:PPLXF)

Arexis AB* (Sweden)

PPL is selling its technology in recombinant bile salt stimulated lipase to Arexis

Arexis is paying £140,000 (US$262,000) for the technology; the deal follows termination of a deal in that area between Astra- Zeneca plc and PPL (2/11)

Praecis Pharmaceuticals Inc. (PRCS)

Neurochem Inc. (Canada; NRMX)

Neurochem licensed certain beta amyloid peptides for use in a vaccine to prevent and treat Alzheimer's disease

Neurochem would own resulting products; terms were not disclosed (1/20)

Promega Corp.*

Chemicon International Inc. (unit of Serologicals Corp.; SERO)

Chemicon got a sublicense to use RNA interference technology; Promega holds rights from Benitec Ltd.

Chemicon can develop and sell ddRNAi-based products and reagents for life science research; terms were not disclosed (2/17)

ProSkelia SAS* (France)

BioXell SpA* (Italy)

Collaboration to develop drugs based on vitamin D3 analogues for treating osteoporosis and secondary hyperparathyroidism

Companies are pooling their technologies in the collaboration, will jointly develop candidates, and would share any resulting revenues (1/12)

Ribopharma AG* (Germany; affiliate of Alnylam Pharmaceuticals Inc.)

RNAx GmbH* (Germany)

Agreement under which RNAx was granted a non-exclusive license to market research services under a patent in RNA interference

RNAx will pay initial and annual license fees, as well as royalties on sales of licensed services (1/27)

Ribopharma AG* (Germany; affiliate of Alnylam Pharmaceuticals Inc.)

Cell Signaling Technology Inc.*

Agreement under which Cell Signaling was granted a nonexclusive license to market research services under a patent in RNA interference

CST will pay initial and annual fees, as well as royalties on sales of resulting products; the patent covers the use of short double-stranded RNAs to mediate RNAi (1/13)

Ribopharma AG* (Germany; affiliate of Alnylam Pharmaceuticals Inc.)

Invitrogen Corp. (IVGN)

Agreement under which Invitrogen was granted a non- exclusive license to market research services under a patent in RNA interference

Terms of the deal were not disclosed; the patent covers the use of short double-stranded RNAs to mediate RNAi (1/13)

Ribopharma AG* (Germany; affiliate of Alnylam Pharmaceuticals Inc.)

Cenix BioScience GmbH* (Germany)

Agreement under which Cenix was granted a nonexclusive license to market research services under a patent in RNA interference

Cenix will pay annual fees and royalties on sales of licensed services; the patent covers the use of short double-stranded RNAs to mediate RNAi (1/13)

Syrrx Inc.*

Fluidigm Corp.*

Fluidigm obtained license rights directed to the submicroliter crystallization of proteins

Fluidigm will use the license in its Topaz system for protein crystallization; terms of the nonexclusive deal were not disclosed (2/3)

Tripos Inc. (TRPS)

Chronogen Inc.*

Tripos will provide drug discovery services for Chronogen in a collaboration to develop drugs for cardiovascular disorders

The collaboration has a three-year term; terms of the deal were not disclosed (1/13)

VaxGen Inc. (VXGN)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

Collaboration under which VaxGen will support development and manufacturing of Avanir's anthrax antibody

Terms of the cross-license and research deal related to preclinical supplies of the antibody were not disclosed (1/29)

ViaCell Inc.*

Amgen Inc. (AMGN)

Collaboration and license agreement in cellular therapy; ViaCell gets licenses to certain cellular growth factors

Amgen gets rights to collaborate in development of resulting products, is investing $20M in ViaCell, and would pay milestones upon any approval; they would share profits from any approved product (12/31)

Viatris GmbH and Co.* (Germany)

Xcel Pharmaceuticals Inc.*

Xcel acquired exclusive worldwide rights to retigabine, which has completed Phase II trials in epilepsy

Xcel plans to begin a Phase III program in 2005; terms of the deal were not disclosed (2/2)

Virogen Ltd.* (UK)

Micrologix Biotech Inc. (Canada; TSE:MBI)

Micrologix acquired global rights to celgosivir, a Phase I/II compound for hepatitis C

Virogen will get an up-front equity investment and could get milestone payments, sales royalties and revenue from sublicences; specific terms were not disclosed (2/3)

Xencor Inc.*

Protein Design Labs Inc. (PDLI)

Collaboration that will allow PDL to use Xencor's XmAb technology on preclinical-stage antibodies against a number of PDL targets

Xencor will receive technology access and license fees, and potential development milestones and royalties; PDL would be responsible for development (1/12)

Xigen SA* (Switzerland)

Auris Medical AG* (Switzerland)

Auris obtained an exclusive license to Xigen's intracellular peptides for developing products for ear disorders

Xigen got an up-front payment and could get milestones and royalties; the companies also are going to collaborate on developing products for inner-ear disorders (2/5)

XOMA Ltd. (XOMA)

Diversa Corp. (DVSA)

Agreement under which Diversa gets a license to use XOMA's antibody expression technology, and an option to a license for producing antibodies

Xoma will get a license fee and potential milestones and royalties; the companies will work together to develop antibodies for autoimmune diseases; Diversa will get research funding and also could get milestone and royalty payments (1/6)

ZymeQuest Inc.*

Chiron Corp. (CHIR)

Partnership to develop and sell ZymeQuest's enzymatic conversion system, which converts red blood cells to enzyme-converted Group O red blood cells

Chiron will share in development costs, make an equity investment in ZymeQuest and get worldwide marketing and commercialization rights for the technology; terms were not disclosed (1/5)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.